TW202031255A - 血漿激肽釋放酶抑制劑之結晶鹽 - Google Patents
血漿激肽釋放酶抑制劑之結晶鹽 Download PDFInfo
- Publication number
- TW202031255A TW202031255A TW108139655A TW108139655A TW202031255A TW 202031255 A TW202031255 A TW 202031255A TW 108139655 A TW108139655 A TW 108139655A TW 108139655 A TW108139655 A TW 108139655A TW 202031255 A TW202031255 A TW 202031255A
- Authority
- TW
- Taiwan
- Prior art keywords
- crystalline salt
- salt
- xrpd
- compound
- ray powder
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physiology (AREA)
- Ophthalmology & Optometry (AREA)
- Food Science & Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Polymers & Plastics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Mycology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862754983P | 2018-11-02 | 2018-11-02 | |
| US62/754,983 | 2018-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202031255A true TW202031255A (zh) | 2020-09-01 |
Family
ID=70457981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108139655A TW202031255A (zh) | 2018-11-02 | 2019-11-01 | 血漿激肽釋放酶抑制劑之結晶鹽 |
Country Status (22)
| Country | Link |
|---|---|
| US (11) | US10662160B1 (https=) |
| EP (1) | EP3873463A4 (https=) |
| JP (2) | JP2022505670A (https=) |
| KR (1) | KR102810837B1 (https=) |
| CN (1) | CN112969458A (https=) |
| AR (1) | AR116951A1 (https=) |
| AU (1) | AU2019374115B8 (https=) |
| BR (1) | BR112021008249A2 (https=) |
| CA (1) | CA3117123A1 (https=) |
| CL (1) | CL2021001094A1 (https=) |
| CO (1) | CO2021007172A2 (https=) |
| EA (1) | EA202191192A1 (https=) |
| IL (2) | IL322896A (https=) |
| MA (1) | MA54087A (https=) |
| MX (1) | MX2021004917A (https=) |
| PE (1) | PE20211280A1 (https=) |
| PH (1) | PH12021550883A1 (https=) |
| PY (1) | PY1991831A (https=) |
| SG (1) | SG11202103804TA (https=) |
| TW (1) | TW202031255A (https=) |
| UY (1) | UY38438A (https=) |
| WO (1) | WO2020092898A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102736869B1 (ko) | 2014-03-07 | 2024-12-02 | 바이오크리스트파마슈티컬즈,인코포레이티드 | 인간 혈장 칼리크레인 저해제 |
| UY38438A (es) | 2018-11-02 | 2020-05-29 | Biocryst Pharm Inc | Sales cristalinas de un inhibidor de calicreína plasmática |
| WO2021025969A1 (en) * | 2019-08-02 | 2021-02-11 | Teva Pharmaceuticals International Gmbh | Solid state forms of berotralstat |
| CN116375648A (zh) * | 2023-03-22 | 2023-07-04 | 苏州农平科技发展有限公司 | 贝罗司他中间体的制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559157A (en) * | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| BRPI0519331A2 (pt) | 2004-12-15 | 2009-01-20 | Bristol Myers Squibb Co | formas cristalina de um inibidor de fator xa |
| CN101495468A (zh) * | 2006-07-31 | 2009-07-29 | 艾克提弗赛特制药股份有限公司 | 血浆激肽释放酶抑制剂 |
| WO2008016883A2 (en) | 2006-07-31 | 2008-02-07 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| RU2585683C2 (ru) * | 2010-05-19 | 2016-06-10 | Сандоз Аг | Очистка позаконазола и промежуточных продуктов для синтеза позаконазола |
| US9012464B2 (en) | 2010-11-25 | 2015-04-21 | Ratiopharm Gmbh | Salts and polymorphic forms of Afatinib |
| GB201212081D0 (en) * | 2012-07-06 | 2012-08-22 | Kalvista Pharmaceuticals Ltd | New polymorph |
| KR102736869B1 (ko) * | 2014-03-07 | 2024-12-02 | 바이오크리스트파마슈티컬즈,인코포레이티드 | 인간 혈장 칼리크레인 저해제 |
| DK4019022T3 (en) | 2015-10-01 | 2024-02-19 | Biocryst Pharm Inc | Human plasma kallikrein inhibitors |
| UY38438A (es) | 2018-11-02 | 2020-05-29 | Biocryst Pharm Inc | Sales cristalinas de un inhibidor de calicreína plasmática |
| CN114206839B (zh) | 2019-08-06 | 2025-03-07 | 拜奥克里斯特制药公司 | 血浆激肽释放酶抑制剂的生产规模合成 |
-
2019
- 2019-10-31 UY UY0001038438A patent/UY38438A/es not_active Application Discontinuation
- 2019-10-31 AR ARP190103187A patent/AR116951A1/es unknown
- 2019-11-01 IL IL322896A patent/IL322896A/en unknown
- 2019-11-01 EP EP19877809.4A patent/EP3873463A4/en active Pending
- 2019-11-01 CA CA3117123A patent/CA3117123A1/en active Pending
- 2019-11-01 PE PE2021000587A patent/PE20211280A1/es unknown
- 2019-11-01 PY PY201901991831A patent/PY1991831A/es unknown
- 2019-11-01 CN CN201980072995.3A patent/CN112969458A/zh active Pending
- 2019-11-01 US US16/671,649 patent/US10662160B1/en active Active
- 2019-11-01 MX MX2021004917A patent/MX2021004917A/es unknown
- 2019-11-01 MA MA054087A patent/MA54087A/fr unknown
- 2019-11-01 EA EA202191192A patent/EA202191192A1/ru unknown
- 2019-11-01 WO PCT/US2019/059385 patent/WO2020092898A1/en not_active Ceased
- 2019-11-01 KR KR1020217013734A patent/KR102810837B1/ko active Active
- 2019-11-01 BR BR112021008249-2A patent/BR112021008249A2/pt unknown
- 2019-11-01 TW TW108139655A patent/TW202031255A/zh unknown
- 2019-11-01 SG SG11202103804TA patent/SG11202103804TA/en unknown
- 2019-11-01 AU AU2019374115A patent/AU2019374115B8/en active Active
- 2019-11-01 JP JP2021522086A patent/JP2022505670A/ja active Pending
-
2020
- 2020-02-06 US US16/784,016 patent/US11117867B2/en active Active
-
2021
- 2021-04-20 IL IL282454A patent/IL282454A/en unknown
- 2021-04-21 PH PH12021550883A patent/PH12021550883A1/en unknown
- 2021-04-27 CL CL2021001094A patent/CL2021001094A1/es unknown
- 2021-05-31 CO CONC2021/0007172A patent/CO2021007172A2/es unknown
- 2021-09-02 US US17/465,181 patent/US11618733B2/en active Active
-
2023
- 2023-03-10 US US18/120,073 patent/US12344585B2/en active Active
-
2024
- 2024-05-27 JP JP2024085295A patent/JP2024109860A/ja active Pending
-
2025
- 2025-05-30 US US19/224,669 patent/US20250388545A1/en active Pending
- 2025-08-28 US US19/312,645 patent/US12545645B2/en active Active
- 2025-08-28 US US19/312,656 patent/US12552750B2/en active Active
- 2025-08-28 US US19/313,010 patent/US12590068B2/en active Active
- 2025-08-28 US US19/312,755 patent/US12545646B2/en active Active
- 2025-08-28 US US19/313,046 patent/US12590069B2/en active Active
- 2025-08-28 US US19/312,786 patent/US12545647B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12552750B2 (en) | Crystalline salts of a plasma kallikrein inhibitor | |
| KR102928815B1 (ko) | 혈장 칼리크레인 억제제의 공정-스케일 합성 | |
| HK40052614A (en) | Crystalline salts of a plasma kallikrein inhibitor | |
| OA20652A (en) | Process-scale synthesis of a plasma kallikrein inhibitor. |